New injection aims to heal skin ulcers in rare disease
NCT ID NCT07337564
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an injection called SHR-1139 in 10 adults with ulcerative pyoderma gangrenosum, a rare skin condition that causes painful, open sores. The main goal is to see if the drug can completely close the target ulcer within 12 weeks. Researchers will also check for side effects and partial healing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1139 injection
- What this could lead to
- If it works, this could point toward a new treatment option for pyoderma gangrenosum, helping ulcers heal faster.
- What could go wrong
- This is a very small early-phase trial with only 10 people, so results may not apply broadly. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PYODERMA GANGRENOSUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermatology Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for painful skin ulcers: experimental drug enters human trials
- Can a psoriasis drug heal these stubborn skin ulcers?
- Oxygen chamber therapy put to the test for dozens of diseases
- Promising drug trial for painful skin ulcers halted early
- New wound therapy for rare skin disease shows early promise
- New drug hopes to heal painful skin ulcers in rare disease